Table 3.
Comparison of number of people with MS in validation studies and total number in each country
| Study | Country | Number of people with MS in study | Number of people with MS in country | Percentage in study (%) |
|---|---|---|---|---|
| Costers [40] | Belgium | 97 | 12,000 | 0.81 |
| Dusankova [36] | Czech Republic | 369 | 16,000 | 2.31 |
| Eshaghi [41] | Iran | 156 | 50,000 | 0.31 |
| Giedraitienė [42] | Lithuania | 50 | 2621 | 1.91 |
|
Goretti [43] Niccolai [44] |
Italy | 23 | 68,000 | 0.03 |
| 192 | ||||
| Niino [45] | Japan | 156 | 12,000 | 1.30 |
| O’Connell [46] | Ireland | 67 | 7000 | 0.96 |
| Ozakbas [47] | Turkey | 173 | 40,000 | 0.43 |
| Polychroniadou [48] | Greece | 44 | 7000 | 0.63 |
| Sandi [49] | Hungary | 65 | 20,000 | 0.33 |
| Spedo [50] | Brazil | 58 | 30,000 | 0.19 |
| Strober [10] | United States | 65 | 400,000 | 0.02 |
| Vanotti [51, 52] | Argentina | 50 | 8000 | 0.06 |
| Walker [53] | Canada | 57 | 97,366 | 0.06 |